Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744121 | 0.96 | CA5A (0.39) | CA5ACA5BTSHRCA2CA1 | |
| SCHEMBL14355508 | 0.84 | CA5A (0.36) | CA5ACA5BTSHRCA2CA1 | |
| SCHEMBL3144289 | 0.78 | — | — | |
| SCHEMBL3136153 | 0.78 | — | — | |
| SCHEMBL12164283 | 0.78 | — | — | |
| SCHEMBL3145313 | 0.78 | — | — | |
| SCHEMBL14355488 | 0.78 | — | — | |
| SCHEMBL20853612 | 0.78 | — | — | |
| SCHEMBL15203837 | 0.78 | — | — | |
| SCHEMBL380314 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-08-02 | — | — | US | claimed |
| WO-2010141883-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-09 | — | — | WO | claimed |
| US-5124438-A | Reacting with chlorine and sulfonate | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-23 | — | — | US | claimed |
| EP-3077438-B1 | POLYURETHANES HAVING REDUCED EMISSIONS OF ALDEHYDE | BASF SE (DE) | 2018-03-07 | — | — | EP | disclosed |
| US-9365545-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-9108921-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014139144-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20130030179-A1 | PROCESS FOR THE PREPARATION OF VARENICLINE | DIPHARMA FRANCIS S.R.L. (IT) | 2013-01-31 | — | — | US | disclosed |
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-08-02 | — | — | US | disclosed |
| EP-0382054-B1 | Chemically modified proteins | BASF AG (DE) | 1995-04-26 | — | — | EP | disclosed |
| US-5124438-A | Reacting with chlorine and sulfonate | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-23 | — | — | US | disclosed |
| EP-0382054-A2 | Chemically modified proteins | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
| EP-0175364-B1 | PROCESS FOR THE PREPARATION OF ALPHA-BETA-DIAMINOACRYLNITRILES | BASF Aktiengesellschaft (DE) | 1990-06-06 | — | — | EP | disclosed |
| US-4880934-A | Preparation of hydroxyalkylpiperazinones by reacting a 2,3-dihydroxy-1,4-dioxane with a hydroalkyldiamine | THE DOW CHEMICAL COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| US-4814443-A | Preparation of hydroxyalkylpiperazinones by reacting glyoxal with hydroxyalkyldiamines | THE DOW CHEMICAL COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| US-4734499-A | Preparation of α,β-diaminoacrylonitriles | BASF AKTIENGESELLSCHAFT (DE) | 1988-03-29 | — | — | US | disclosed |
| EP-0175364-A2 | Process for the preparation of alpha-beta-diaminoacrylnitriles | BASF Aktiengesellschaft (DE) | 1986-03-26 | — | — | EP | disclosed |
| US-4216163-A | SEQUESTERING AGENTS | BENCKISER-KNAPSACK GMBH (DE) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | HLA-DRB1, MICA, CD74 | CA5A 295/4885CA5B 145/4885TSHR 2035/4885 |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | CA5A 356/4885CA5B 576/4885TSHR 3332/4885 |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | CA5A 356/4885CA5B 576/4885TSHR 3332/4885 |
| US-20130030179-A1 | PROCESS FOR THE PREPARATION OF VARENICLINE | NOX4, SMOX, CYP3A7 | CA5A 429/4885CA5B 213/4885TSHR 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.